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http://dx.doi.org/10.1016/j.neuron.2014.11.007SUMMARY (Geddes et al., 2000). However, current antipsychotics areCurrent antipsychotic drugs primarily target dopa-
mine D2 receptors (D2Rs), in conjunction with other
receptors such as those for serotonin. However,
these drugs have serious side effects such as extra-
pyramidal symptoms (EPS) and diabetes. Identifying
a specific D2R signaling pathway that could be tar-
geted for antipsychotic effects, without inducing
EPS, would be a significant improvement in the treat-
ment of schizophrenia. We report here that the D2R
forms a protein complex with Disrupted in Schizo-
phrenia 1 (DISC1) that facilitates D2R-mediated
glycogen synthase kinase (GSK)-3 signaling and
inhibits agonist-induced D2R internalization. D2R-
DISC1 complex levels are increased in conjunction
with decreased GSK-3a/b (Ser21/9) phosphorylation
in both postmortem brain tissue from schizophrenia
patients and in Disc1-L100P mutant mice, an animal
model with behavioral abnormalities related to
schizophrenia. Administration of an interfering pep-
tide that disrupts the D2R-DISC1 complex success-
fully reverses behaviors relevant to schizophrenia
but does not induce catalepsy, a strong predictor
of EPS in humans.
INTRODUCTION
Schizophrenia is a chronic mental illness, characterized by epi-
sodes of psychotic symptoms in addition to cognitive and social
impairments that emerge in early adulthood. Dopamine D2 re-
ceptors (D2Rs) are the main target of antipsychotic medications,
and the clinical potency of antipsychotic drugs is correlated with
D2R binding affinity (Seeman et al., 1976). Some antipsychotics
also block serotonin 2A receptors (5-HT2AR) in addition to D2R1302 Neuron 84, 1302–1316, December 17, 2014 ª2014 Elsevier Incineffective for controlling psychotic symptoms in many patients,
and even with good symptom control, functional outcomes
remain poor (Insel and Scolnick, 2006; Lieberman et al., 2005).
In addition, current antipsychotic drugs cause serious side
effects, including extrapyramidal symptoms (EPS), tardive dyski-
nesia, sexual dysfunction, weight gain, and diabetes (Leucht
et al., 2009). Thus, understanding the details of D2R signaling
is critical for the identification of novel therapeutic targets to
develop more effective antipsychotic drugs with fewer side
effects.
D2Rs are G protein-coupled receptors (GPCRs) that activate
both G protein-coupled signaling cascades and non-G protein
pathways (Missale et al., 1998; Beaulieu et al., 2009). D2Rs
couple with Gi/Go proteins to control adenylate cyclase activity,
phosphatidylinositol turnover, arachidonic acid release, inwardly
rectifying K+ and Ca2+ channels, and mitogen-activated protein
kinases (Missale et al., 1998). D2Rs also signal through G pro-
tein-independent mechanisms such as b-arrestin2, which leads
to formation of a complex that includes protein phosphatase 2A
(PP2A), Akt, and activation of theGSK-3 pathway (Beaulieu et al.,
2009). A primary mechanism for regulating D2Rs is kinase-medi-
ated desensitization, endocytosis, and endosomal trafficking
that is initiated by GPCR kinase phosphorylation. This in turn
leads to the formation of a complex with b-arrestin, adaptor pro-
tein-2, and clathrin (Hanyaloglu and von Zastrow, 2008). D2R
function is also regulated by various interacting proteins that
modulate its signaling, trafficking, and stability (Fukunaga and
Shioda, 2012; Fuxe et al., 2012). These D2R-associated protein
complexes are therefore potential targets for new treatments.
DISC1 is a susceptibility gene for schizophrenia and other psy-
chiatric disorders, originally identified in a Scottish family with a
high frequency of mental illness (Brandon and Sawa, 2011;
Hodgkinson et al., 2004; Porteous et al., 2011; Taylor et al.,
2003). DISC1 is a scaffold protein that interacts withmany impor-
tant signaling molecules including GSK-3 (Duan et al., 2007;
Kvajo et al., 2008; Lee et al., 2011; Mao et al., 2009; Niwa
et al., 2010; Pletnikov et al., 2008; Shen et al., 2008). As a result,.
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interacting proteins and pathways that has various functions
depending on the developmental stage, signaling pathway,
and brain region (Enomoto et al., 2009; Kim et al., 2009, 2012;
Singh et al., 2010). There are several types of genetic mouse
models for Disc1: the 129S6/SvEv strain, N-ethyl-N-nitrosourea
(ENU)-induced mutants, siRNA knockdown, and transgenics.
The Disc1-L100P (334T/C) mutation produces abnormalities
consistent with schizophrenia: enlarged lateral ventricles,
abnormal cortical lamination, abnormal prepulse inhibition
(PPI), disrupted latent inhibition, and decreased social interac-
tion (Clapcote et al., 2007; Lee et al., 2011). The behavioral
abnormalities are ameliorated by antipsychotic medications.
In this study, we sought to identify D2R-interacting proteins
that might be potential targets for new antipsychotic treatments.
Since DISC1 is a scaffold protein implicated in schizophrenia,
and since the D2R is the main target of antipsychotic drugs,
we hypothesized that these two proteins interact to modulate
the downstream GSK-3 signaling pathway. We also predicted
an increased D2R-DISC1 interaction in postmortem brain from
schizophrenia patients and in mouse models of schizophrenia.
Having confirmed these predictions, we developed a peptide
that disrupts the D2R-DISC1 interaction. This peptide exerts
antipsychotic-like effects without inducing EPS and affects
D2R signaling through GSK-3. Thus, we have demonstrated a
strategy to achieve greater pharmacological specificity by
targeting interactions between a neurotransmitter receptor and
accessory proteins, rather than simply blocking the receptor
itself. Our results could represent a more general approach to
improve efficacy and reduce side effects for other medications
that target neurotransmitter receptors.
RESULTS
D2R-DISC1 Complex Formation Is Enhanced in
Postmortem Brain Tissue from Schizophrenia Patients
We initially tested whether DISC1 forms a protein complex with
D2R. As shown in Figure 1A (top panel), a D2R antibody, but
not a dopamine D1 receptor (D1R) antibody, coimmunoprecipi-
tated with DISC1 in proteins extracted from rat striatum,
suggesting the existence of a D2R-DISC1 complex. The coim-
munoprecipitation of D1R with D2R (Pei et al., 2010) but not
with DISC1 verified both the efficiency and the specificity of
the D2R antibody for immunoprecipitation. The specificity of
the D2R antibody was also validated in D2R knockout mice
(Figure S1A available online). Conversely, DISC1 antibody coim-
munoprecipitated with D2R (Figure 1A, bottom panel), confirm-
ing the existence of a D2R-DISC1 complex in rat striatum.
We hypothesized that D2R activation should alter D2R-DISC1
complex formation if the D2R-DISC1 interaction participates in
D2R signaling. To investigate this possibility, we examined the
D2R-DISC1 interaction using coimmunoprecipitation in rat pri-
mary striatal neuron cultures and in HEK293T cells expressing
HA-D2R and GFP-DISC1, treated with/without a specific D2R
agonist or antagonist. Activation of D2R with 10 mM quinpirole
(30 min) significantly increased the D2R-DISC1 interaction in
both striatal neurons (Figures 1B and 1C) and in transfected
HEK293T cells (Figures S1B and S1C). The quinpirole effectNecould be blocked by haloperidol, a specific D2R antagonist.
These data suggest that activation of D2R facilitates D2R-
DISC1 complex formation.
As a hyperdopaminergic state has been reported in schizo-
phrenia (Seeman et al., 1976), we reasoned that the D2R-
DISC1 complex may be increased in schizophrenia. We first
tested our hypothesis by carrying out coimmunoprecipitation
experiments on Disc1-L100P mice, as these mice display
behaviors relevant to schizophrenia, including increased loco-
motor activity and disrupted PPI, all of which can be reversed
by treatment with D2R antagonists such as haloperidol
(Clapcote et al., 2007). As shown in Figures 1D and 1E, coimmu-
noprecipitation of DISC1 by the D2R antibody was significantly
higher in Disc1-L100P mice versus wild-type (WT) mice
(p < 0.01). There was no significant difference in direct immuno-
precipitation of D2R between Disc1-L100P and WT mice
(Figures 1D and 1F). To obtain direct evidence demonstrating
that the L100P mutation alters the D2R-DISC1 interaction,
we measured D2R-DISC1 complex levels in HEK293T cells
coexpressing HA-D2R with either Disc1-L100P or WT DISC1.
As shown in Figures S1D and S1E, coimmunoprecipitation
results show that D2R-DISC1 interaction is significantly higher
in D2R/Disc1-L100P coexpressing cells compared to D2R/WT-
DISC1 cells.
We then measured D2R-DISC1 complex levels in postmortem
striatum samples from the Stanley Medical Research Institute,
consisting of 15 schizophrenia and 15 unaffected control sub-
jects matched for age, sex, race, postmortem interval, pH, side
of brain, andmRNA quality (Torrey et al., 2000). Demographic in-
formation including antipsychotic use is shown in Tables S1 and
S2. Equal amounts of protein from each sample were incubated
with anti-D2R antibody, and the precipitated proteins were
immunoblotted with either DISC1 or D2R antibody. Each west-
ern blot included five samples from each group, and results for
each sample are presented as the percentage of the mean of
five control samples on the same blot. As shown in Figures 1G
and 1H, coimmunoprecipitation of DISC1 by the D2R antibody
was significantly increased in schizophrenia postmortem brain
samples compared to control (n = 15, p < 0.05). The levels of
directly immunoprecipitated D2R were not significantly different
between the two groups (Figures 1G and 1I).
One potential confounding factor in this postmortem analysis
is antipsychotic treatment, since most (14/15) of the schizo-
phrenia patients were treated with antipsychotics (Table S1).
To address this issue, we tested whether haloperidol enhances
the D2R-DISC1 interaction in Disc1-L100P mice. As shown in
Figures S1F and S1G, both acute (1 mg/kg subcutaneously
[s.c.]) and chronic (1 mg/kg/day s.c. 14 days) haloperidol treat-
ment significantly reduced D2R-DISC1 interaction in Disc1-
L100P mice. Thus, antipsychotic treatment is unlikely to be the
cause of increased D2R-DISC1 complex levels.
DISC1 Facilitated D2R-Induced Reduction of GSK-3
Phosphorylation
To investigate the function of the D2R-DISC1 complex, we
sought to determine whether DISC1 played a role in D2R-medi-
ated GSK-3 signaling. Prior studies on D2R-mediated modula-
tion of GSK-3 phosphorylation were carried out exclusively inuron 84, 1302–1316, December 17, 2014 ª2014 Elsevier Inc. 1303
Figure 1. Regulation of D2R-DISC1 Complex Formation
(A) In rat brain striatal lysate, D2R antibody, but not D1R antibody or IgG (negative control), coimmunoprecipitated with DISC1 (top panel); DISC1 antibody
coimmunoprecipitated with D2R (bottom panel).
(B) Coimmunoprecipitation shows that activation of D2R facilitates D2R-DISC1 complex formation in cell lysate from striatal neurons pretreated with quinpirole
(Quin) or haloperidol (halo)/Quin.
(C) Densitometric analysis of DISC1 coimmunoprecipitated by D2R from cultured rat striatal neurons pretreated with quinpirole or halopirodol/quinpirole.
*p < 0.05 compared to controls. #p < 0.05 compared to the Quin group. One-way ANOVA. n = 3.
(D) Coimmunoprecipitation shows higher D2R-DISC1 complex levels in Disc1-L100P mouse striatum compared to WT mice.
(E and F) Densitometric analysis of the level of DISC1 and D2R. **p < 0.01, n = 5/6, t test.
(G–I) Coimmunoprecipitation shows significantly more D2R-DISC1 complex in striatal postmortem brain samples from schizophrenia (SZ) patients compared to
controls (CTRL). Representative Western blot of DISC1 and D2R precipitated by D2R antibody (G). The intensity of each protein band for DISC1 (H) and D2R (I)
was quantified by densitometry. Results for each sample are presented as the percentage of the mean of the control samples on the same blot. *p < 0.05, n = 15,
t test.
All data are shown as means ± SEM. See also Figure S1 and Tables S1 and S2.
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Figure 2. DISC1 Modulates D2R-Mediated GSK-3 Phosphorylation
(A) Western blot analysis shows that activation of D2R with quinpirole reduces GSK-3a/b (Ser21/9) phosphorylation in HEK293T cells expressing D2R and DISC1
but not in HEK293 cells expressing D2R with pcDNA3. GSK-3a/b was used as a loading control.
(B and C) Densitometric analysis of phosphorylated GSK-3a/b (Ser21/9). *p < 0.05, n = 6, t test.
(D) Western blot analysis shows that activation of D2R reduces GSK-3a/b (Ser21/9) phosphorylation in rat striatal neurons. The D2R effect can be blocked by the
D2R antagonist haloperidol.
(E) Densitometric analysis of the intensity of phosphorylated GSK-3a/b (Ser21/9). *p < 0.05, n = 4, One-way ANOVA.
(F) Western blot analysis shows that activation of D2R reduces AKT (Thr308) phosphorylation in rat striatal neurons. The D2R effect can be blocked by the D2R
antagonist haloperidol. AKT was used as a loading control.
(G) Densitometric analysis of the intensity of phosphorylated AKT (Thr308). *p < 0.05, n = 3, One-way ANOVA.
(H) Representative western blot shows that GSK-3a/b (Ser21/9) phosphorylation was reduced in postmortem striatal tissue of schizophrenia patients (SZ)
compared to control subjects (control).
(I and J) Densitometric analysis of the intensity of phosphorylated GSK-3a/b. t test, n = 15, *p < 0.05.
All data are shown as means ± SEM. See also Figures S2–S4.
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2007, 2009; Beaulieu, 2012). Thus, an initial step to investigate
the role of DISC1 in D2R-mediated GSK-3 signaling is to
compare D2R-induced changes in GSK-3 phosphorylation in
HEK293T cells coexpressing DISC1 and D2R to HEK293T cellsNeexpressing D2R alone. As shown in Figures 2A–2C, preincuba-
tion with 10 mM quinpirole (30 min) significantly reduces GSK-3
a/b Ser-21/9 phosphorylation, but not GSK3a/b (Y-279/216)
phosphorylation, in HEK293T cells coexpressing D2R and
DISC1, while quinpirole has no such an effect in HEK293T cellsuron 84, 1302–1316, December 17, 2014 ª2014 Elsevier Inc. 1305
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a/b Ser-21/9 phosphorylation is also observed in rat striatal neu-
rons (Figures 2D and 2E), which is consistent with previous
observations in mouse striatum (Beaulieu et al., 2007, 2009;
Beaulieu, 2012). In contrast, the D2R-mediated reduction of
GSK-3 a/b Ser-21/9 phosphorylation is not observed in D2R
knockout mice (Figures S2A and S2B). Furthermore, activation
of D2R failed to modulate GSK-3 a/b Ser-21/9 phosphorylation
in rat cortical neurons (Figures S2C and S2D), although coimmu-
noprecipitation of DISC1 by the D2R antibody is observed
(Figure S2E).
To further confirm the role of DISC1 in the modulation of D2R
effects on GSK-3 phosphorylation, we knocked down the
expression of DISC1 using DISC1-shRNA as previously
described (DISC1-shRNA fromDr. Guo-li Ming at Johns Hopkins
University) (Duan et al., 2007; Zhou et al., 2013). The ability of
DISC1-shRNA to knock down the expression of DISC1 in rat
striatal neurons was confirmed (Figure S3A). We then measured
GSK-3 a/b Ser-21/9 phosphorylation. As shown in Figures S3B–
S3D, DISC1 shRNA treatment significantly decreased the ability
of D2R to reduce GSK-3 a/b Ser-21/9 phosphorylation in rat
striatal neurons. More importantly, the effect of DISC1 shRNA
can be rescued by the expression of shRNA-resistant DISC1
(DISC1R from Dr. Guo-li Ming at Johns Hopkins University)
(Figures S3E–S3G).
As Akt phosphorylation is a critical step in D2R-mediated
GSK-3 signaling, we also testedwhether activation of D2Rwould
alter Akt phosphorylation in rat striatal neurons. As shown in
Figures 2F and 2G, quinpirole stimulation decreased Akt phos-
phorylation at Thr-308 but not at Ser-473 site, consistent with
previous studies (Beaulieu et al., 2007). In addition, DISC1
shRNA treatment also decreased the ability of D2R to reduce
Akt phosphorylation at Thr-308 site in rat striatal neurons
(Figures S4A–S4C). Furthermore, we tested whether DISC1 is
required for D2R-mediated cAMP accumulation, the classic
signaling pathway for D2R. HEK293T cells coexpressing
DISC1 and D2R and HEK293T cells expressing D2R alone
were treated with forskolin (1 mM, 10 min), with or without
pretreatment with 10 mM quinpirole (30 min). As shown in
Figure S4D, there is no difference in D2R-mediated cAMP accu-
mulation between these two groups. Thus, DISC1 may selec-
tively modulate D2R-mediated activation of the GSK-3 signaling
pathway.
GSK3a/b Phosphorylation Is Decreased in Postmortem
Brain Tissue from Schizophrenia Patients
Previous studies have shown that antipsychotics target GSK-3
signaling (Beaulieu et al., 2009), implicating GSK-3 in the treat-
ment of schizophrenia. To investigate the functional conse-
quence of elevated DISC1-D2R complex levels in schizophrenia,
we measured GSK3a/b phosphorylation in these samples
compared to controls. As shown in Figures 2H–2J, GSK3a/b
Ser-21/9 phosphorylation is significantly decreased in postmor-
tem striatal tissue from schizophrenia patients compared to con-
trol subjects (p < 0.05, n = 15). This suggest that enhanced
DISC1-D2R complex formation may lead to increased GSK-3
signaling as part of the mechanism underlying the pathophysi-
ology of schizophrenia.1306 Neuron 84, 1302–1316, December 17, 2014 ª2014 Elsevier IncDevelopment of an Interfering Peptide that Is Able
to Disrupt DISC1-D2R Complex
If the D2R-DISC1 interaction plays a role in D2R-mediated mod-
ulation of GSK-3 signaling, we predicted that disruption of the
interaction should abolish D2R-mediated modulation of GSK-3
signaling. More importantly, if the enhanced D2R-DISC1 com-
plex indeed plays a role in the pathophysiology of schizophrenia,
disrupting the complex should have antipsychotic effects. To
develop an interfering peptide, we identified the regions of the
D2R that are essential for D2R-DISC1 complex formation. We
initially used GST-fusion proteins encoding fragments of intra-
cellular domains of D2R to affinity purify DISC1 in rat striatal
extracts. GST-fusion proteins encoding the carboxyl tail (CT) of
D2R (D2CT: T428-C443) and the third intracellular loop (IL3) of
D2R (D2IL3: K211-Q373) were made and used for affinity purifica-
tion. As shown in Figure 3A, GST-D2IL3, but not GST-D2CT,
precipitates DISC1, suggesting that D2IL3 is involved in the
DISC1-D2R interaction. Using the same strategy, we further
dissected the D2IL3 into smaller fragments (Figure S5A) and
concluded that D2IL3-1-1[K211-T225] is the region interacting with
DISC1 (Figures 3B and 3C). Furthermore, we found that in-vitro-
translated full-length [35S]-DISC1 probe specifically hybridized
with the K211-T225 fragment (Figure 3D), suggesting that the
D2R and DISC1 interact with each other directly.
Using the same experimental approach, we identified that the
NT region of DISC1 is responsible for its interaction with D2R,
because the [35S]-DISC1NT probe, but not the [
35S]-DISC1CT
probe, specifically hybridized with the D2IL3-1-1 [K211-T225] frag-
ment (Figure 3E). Based on the sequence of K211-T225, we syn-
thesized a peptide: D2pep[K211-T225] (KIYIVLRRRRKRVNT). If
the K211-T225 region is essential for D2R to interact with DISC1,
application of D2pep[K211-T225] should disrupt the D2R-DISC1
interaction by competing with D2R for DISC1. As expected,
D2pep[K211-T225] (10 mM), but not the scrambled control peptide
(D2pep-sc) (VLRKTRIRRYKIRNV), inhibited D2R-DISC1 com-
plex formation in rat striatum (Figure 3F) and agonist-induced
increase in D2R-DISC1 complex formation in HEK293T cells
coexpressing HA-D2R and GFP-DISC1 (Figure 3G). The ability
of D2pep to inhibit D2R-DISC1 complex formation was also
observed in rat striatal neurons pretreated with TAT-D2pep
(10 mM, 1 hr) (Figure 3H). To allow D2pep[K211-T225] to penetrate
into cells, it was fused to the cell membrane transduction domain
of the human immunodeficiency virus-type 1 TAT protein, as pre-
viously described (Lee et al., 2007; Pei et al., 2010). Thus, we
concluded that the K211-T225 region of D2R is critical for D2R-
DISC1 complex formation and that the D2pep[K211-T225] peptide
disrupts the D2R-DISC1 complex.
Disruption of DISC1-D2R Interaction Blocks D2R-
Mediated Modulation of GSK-3a/b Phosphorylation
Since D2pep[K211-T225] disrupts the D2R-DISC1 interaction, we
tested whether pretreatment with D2pep[K211-T225] blocked
D2R-mediated modulation of GSK-3a/b phosphorylation. The
ability of D2R activation to modulate GSK-3a/b Ser-21/9 phos-
phorylation was significantly inhibited by preincubating with
TAT-D2pep[K211-T225] peptide (10 mM, 1 hr), but not with the
scrambled peptide TAT-D2pep-sc in both HEK293T cells coex-
pressing D2R and DISC1 (Figures S5B and S5C), and in rat.
Figure 3. DISC1 Forms a Complex with D2R via the K211-T225 Region of the IL3 of D2R
(A) Western blot showing that GST-D2IL3, but not GST-D2CT, can ‘‘pull down’’ DISC1 from rat striatal tissue.
(B) Western blot showing that GST-D2IL3-1, but not GST-D2IL3-2 or GST-D2IL3-3, can ‘‘pull down’’ DISC1 from rat striatal tissue.
(C) Western blot showing that GST-D2IL3-1-1, but not GST-D2IL3-1-2, GST-D2IL3-1-3 or GST-D2IL3-1-4, can ‘‘pull down’’ DISC1 from rat striatal tissue.
(D) GST-D2IL3-1 and GST- D2IL3-1-1 directly bind to DISC1 in vitro. GST-D2IL3-1, GST-D2IL3-1-1, GST-D2IL3-1-2, GST-D2IL3-1-3, and GST-D2IL3-1-4 were incubated
with [35S]-DISC1, and the precipitated proteins were subjected to SDS-PAGE.
(E) GST-D2IL3-1-1 directly binds to DISC1NT in vitro. GST-D2IL3-1, GST-D2IL3-1-1, GST-D2IL3-1-2, GST-D2IL3-1-3, and GST-D2IL3-1-4 were incubated with [
35S]-
DISC1NT or [
35S]-DISC1CT, and the precipitated proteins were subjected to SDS-PAGE.
(F) Coimmunoprecipitation shows that D2pep[K211-T225], but not D2pep-sc, is able to disrupt the DISC1-D2R complex in rat brain striatal lysate.
(G) Coimmunoprecipitation shows that D2pep[K211-T225] (D2), but not D2pep-sc (Sc), is able to block quinpirole facilitated DISC1-D2R complex formation in cell
lysate from HEK293T cells expressing GFP-DISC1 and HA-D2R.
(H) Coimmunoprecipitation shows that D2pep[K211-T225], but not D2pep-sc, is able to disrupt the DISC1-D2R complex in striatal neurons.
See also Figure S5A.
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suggest that the D2R-mediated modulation of GSK-3a/b phos-
phorylation is dependent on D2R- DISC1 interaction.
As well, the D2R-mediated modulation of Akt phosphorylation
can be blocked by the TAT-D2pep [K211-T225], but not the scram-
bled peptide TAT-D2pep-sc in rat striatal neurons (Figures 4C
and 4D). Furthermore, we found that the ability of D2R activation
to inhibit forskolin-induced cAMP accumulation was not
changed by preincubating with TAT-D2pep[K211-T225] or TAT-NeD2pep-sc in HEK293T cells (Figure S5D). Similar results were
also observed in striatal neurons with lentivirus-mediated over-
expression of DISC1 (Figure S5E). These data provide further ev-
idence that the D2R-DISC1 interaction is selectively involved in
D2R-mediated activation of the GSK-3 signaling pathway, which
is also specifically targeted by TAT-D2pep[K211-T225].
We next tested whether GSK3a/b phosphorylation is altered
in Disc1-L100P mice and, if so, whether disruption of the
D2R-DISC1 complex can rescue the changes in GSK3a/buron 84, 1302–1316, December 17, 2014 ª2014 Elsevier Inc. 1307
Figure 4. Disruption of D2R-DISC1 Interac-
tion Blocked D2R-Mediated Modulation of
GSK-3 Signaling
(A) Western blot showing that TAT-D2pep[K211-
T225], but not TAT-D2pep-sc, blocked quinpirole-
induced modulation of GSK-3 phosphorylation in
rat striatal neurons.
(B) Densitometric analysis of phosphorylated
GSK-3a/b in striatal neurons. *p < 0.05, n = 3, two-
way ANOVA.
(C) Western blot showing that TAT-D2pep[K211-
T225], but not TAT-D2pep-sc, blocked quinpirole-
induced modulation of AKT phosphorylation in rat
striatal neurons.
(D) Densitometric analysis of phosphorylated AKT.
*p < 0.05, n = 3, two-way ANOVA.
(E) Western blot showing that TAT-D2pep[K211-
T225], but not TAT-D2pep-sc, blocked the
decreased GSK-3a/b (Ser21/9) phosphorylation in
Disc1-L100P mice.
(F) Densitometric analysis of phosphorylated
GSK-3a/b. n = 3, *p < 0.05, **p < 0.01 compared to
WT, ##p < 0.01, ###p < 0.001 compared to
L100P+TAT-D2pep-sc, one-way ANOVA.
All data are shown as means ± SEM. See also
Figures S5B–S5E and S6.
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shown in Figures 4E and 4F, GSK3a/b phosphorylation is signif-
icantly decreased in Disc1-L100P mice. More importantly, intra-
peritoneal (i.p.) injection of TAT-D2pep[K211-T225] (3 nmol/g), but
not the scrambled TAT-D2pep (TAT-D2pep-sc), restored
GSK3a/b phosphorylation in Disc1-L100P mice. Similar effects
were also observed in Disc1-L100P mice with acute (1 mg/kg
s.c.) (Figures S6A and S6B) and chronic (1 mg/kg s.c.14 days)
(Figures S6C and S6D) haloperidol treatment, as well as chronic
TAT-D2pep[K211-T225] treatment (3 nmol/g i.p. daily for 7 days)
(Figures S6E and S6F).
D2R-DISC1 Interaction Inhibits Agonist-Induced D2R
Internalization
We have shown that D2R-DISC1 complex formation facilitates
D2R-mediated GSK-3 signaling. As a GPCR, control of mem-
brane expression is one of the major mechanisms regulating
D2R function. Thus, we examined whether coexpression of1308 Neuron 84, 1302–1316, December 17, 2014 ª2014 Elsevier Inc.DISC1 changed agonist-induced D2R
internalization. We used a biotinylation
assay to selectively label internalized
D2R. HEK293T cells expressing D2R
with or without DISC1 were first labeled
with sulfo-NHS-SS-biotin and then
treated with 10 mM quinpirole (30 min).
Subsequently, all cell surface biotin was
cleaved by using glutathione (GSH), leav-
ing only the endocytosed proteins labeled
with biotin. The ability of GSH to cleave all
cell surface biotin was confirmed with a
negative control. The proteins were ex-
tracted and purified using streptavidinbeads to harvest internalized biotinylated proteins. As shown in
Figures 5A and 5B, western blots of streptavidin-purified protein
extracts show less biotinylated D2R in cells coexpressing DISC1
andpretreatedwith quinpirole compared to cells expressingD2R
alone, suggesting that DISC1 may inhibit agonist-induced
D2R internalization. There was no significant difference in total
D2R expression. Furthermore, pretreatment with TAT-D2pep
[K211-T225], but not TAT-D2pep-sc, blocked DISC1-mediated
inhibition of agonist-induced D2R internalization (Figures 5C
and 5D), suggesting that DISC1 inhibits agonist-induced D2R
internalization through theD2R-DISC1 interaction. Similar results
were also obtained in rat striatal neurons (Figures 5E and 5F).
D2R-DISC1 Interaction Blocks b-arrestin 2-clathrin-AP2
Complex Formation and Facilitates b-arrestin2-PP2A-
Akt Complex Formation
Agonist stimulation of the D2R can lead to both receptor internal-
ization and activation of the GSK-3 pathway; both are potentially
Figure 5. DISC1 Inhibits Agonist-Induced
D2R Internalization
(A) Western blot using anti-HA showing that quin-
pirole-induced internalized HA-D2R proteins (bio-
tinylated cell membrane proteins) are decreased in
HEK293T cells expressing HA-D2R with DISC1
compared to cells expressing HA-D2R alone. ()
control: biotin is cleaved before agonist stimulation.
(+) control: biotin is not cleaved after biotinylation.
(B) Densitometric analysis of D2R biotinylation
assay (relative to untreated cells, mean ± SEM two-
way ANOVA *p < 0.05, n = 3).
(C) Western blot using anti-HA showing TAT-D2pep
[K211-T225] (D2), but not TAT-D2pep-sc (Sc), blocks
DISC1-mediated inhibition of quinpirole-induced
D2R internalization in HEK293T cells expressing
HA-D2R with or without DISC1.
(D) Densitometric analysis of D2R biotinylation
assay (relative to the untreated cells, mean ± SEM,
two-way ANOVA *p < 0.05, n = 3).
(E) Western blot using anti-D2R showing TAT-
D2pep[K211-T225] (D2), but not TAT-D2pep-sc (Sc),
blocks DISC1-mediated inhibition of quinpirole-
induced D2R internalization in striatal neurons.
(F) Densitometric analysis of D2R biotinylation
assay (relative to the group treated with scrambled
peptide without quinpirole, mean ± SEM, two-way
ANOVA **p < 0.01, ***p < 0.001, n = 3).
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that the D2R-DISC1 interaction facilitated activation of the
GSK-3 pathway and downregulates D2R internalization. Thus,
we hypothesized that the D2R-DISC1 interaction facilitates
formation of the b-arrestin2-PP2A-Akt protein complex and in-
hibits formation of the b-arrestin2-clathrin-AP2 complex. The
b-arrestin2-PP2A-Akt complex activates GSK-3 signaling, while
b-arrestin2-clathrin-AP2 is required for D2R endocytosis in
response to agonist activation of D2R.
We initially assessed by coimmunoprecipitation whether the
presence of DISC1 affects b-arrestin2 recruitment to D2R after
agonist stimulation. As shown in Figure 6A, we found that the
presence of DISC1 did not alter the D2R-b-arrestin2 interaction
in HEK293T cells. We obtained similar results in striatal neurons;
agonist stimulation enhanced D2R-b-arrestin2 interaction,
which was unaffected by TAT-D2pep[K211-T225] (Figure 6B).
We then examined the effect of DISC1 on the formation of
the b-arrestin2-clathrin-AP2 and b-arrestin2-PP2A-Akt proteinNeuron 84, 1302–1316, Dcomplexes. As shown in Figure 6C (top
panel), activation of D2R enhanced D2R
coupling with clathrin, and the effect was
blocked by DISC1. In contrast, coexpres-
sion of DISC1 dramatically enhanced
b-arrestin2 coupling with PP2A, which
was further enhanced by D2R activation
(Figure 6D, top panel). These DISC1-asso-
ciated effects were consistently blocked
by TAT-D2pep[K211-T225], but not the con-
trol TAT-D2pep-sc (Figure 6C, bottom
panel; Figure 6D, middle and bottompanel). Similar results were also obtained in rat striatal slices (Fig-
ures 6E and 6F). Therefore, it is likely that the formation of the
DISC1-D2R complex selectively favors D2R-mediated GSK-3
signaling, which would lead to upregulation of the GSK3
pathway.
Disruption of DISC1-D2R Interaction Reverses
Hyperactivity and the Disruption of PPI in
Disc1-L100P Mice
Disc1-L100P mutant mice have relevant behavioral abnormal-
ities including increased locomotor activity and disrupted PPI
that can be reversed by treatment with antipsychotic medica-
tions (Clapcote et al., 2007). If the higher D2R-DISC1 complex
levels in Disc1-L100P mice are part of the pathophysiology of
their abnormal behavior, then disruption of the DISC1-D2R com-
plex with TAT-D2pep[K211-T225] should reverse these abnormal-
ities. Prior to the behavior tests, we first confirmed the ability of
TAT-D2pep[K211-T225] to disrupt the D2R- DISC1 complex inecember 17, 2014 ª2014 Elsevier Inc. 1309
Figure 6. DISC1 Inhibits D2R-Clathrin Com-
plex Formation but Promotes D2R-PP2A
Complex Formation
(A) Coimmunoprecipitation using anti-HA (for D2R)
shows that DISC1 has no effect on quinpirole-
facilitated FLAG-b-arrestin 2-HA-D2R complex
formation in HEK293T cells transfectedwith FLAG-
b-arrestin 2 and HA-D2Rwith/without GFP-DISC1.
(B) Coimmunoprecipitation shows that TAT-D2pep
[K211-T225] (D2) and TAT-D2pep-sc (Sc) has no
effect on quinpirole-facilitated b-arrestin 2-D2R
complex formation in rat striatal neurons.
(C) Coimmunoprecipitation using anti-HA shows
that the presence of DISC1 inhibits quinpirole-
facilitated clathrin-HA-D2R complex formation
(top panel), while TAT-D2pep[K211-T225] (D2) but
not TAT-D2pep-sc (sc) blocks the inhibitory effect
of DISC1 (bottom panel) in HEK293T cells ex-
pressing HA-D2R and Flag-b-arrestin 2 with or
without DISC1.
(D) Coimmunoprecipitation using anti-Flag (for
b-arrestin 2) shows that the presence of DISC1
dramatically enhanced b-arrestin 2 coupling with
PP2A-B and activation of D2R further enhanced
b-arrestin 2 coupling with PP2A-B (top panel),
while TAT-D2pep[K211-T225] (D2), but not TAT-
D2pep-sc (sc), blocks the enhancement induced
by DSIC1 and quinpirole (middle and bottom
panel) in HEK293T cells expressing HA-D2R and
FLAG-b-arrestin 2 with or without DISC1.
(E) Coimmunoprecipitation using anti-b-arrestin 2
shows that TAT-D2pep[K211-T225] (D2), but not
TAT-D2pep-sc (Sc), facilitates b-arrestin 2-clathrin
complex formation in striatal neurons.
(F) Coimmunoprecipitation using anti-b-arrestin 2
shows that TAT-D2pep[K211-T225] (D2), but not
TAT-D2pep-sc (Sc), inhibits b-arrestin 2- PP2A-B
complex formation with or without agonist stimu-
lation in striatal neurons.
Neuron
D2-DISC1 Complex and Antipsychotic EffectsDisc1-L100P mice (Figures S7A–S7D). We also measured the
bioavailability of TAT-D2pep[K211-T225] in plasma and brain of
Disc1-L100P mice at 30, 90, and 150 min after the i.p. injection
(Table S3). As shown in Figure 7A, Disc1-L100P mice treated
with saline or TAT-D2pep-sc were hyperactive compared to
WT mice. This hyperactivity was not observed in Disc1-L100P
mice treated with TAT-D2pep[K211-T225]. Furthermore, Disc1-
L100P mice showed reduced PPI at all prepulse intensities
compared to WT mice. This reduced PPI was restored by TAT-
D2pep[K211-T225] but not TAT-D2pep-sc (Figure 7B). TAT-
D2pep[K211-T225] had no effect on baseline startle response in
Disc1-L100P and WT mice (Table S4). These data suggest that
TAT-D2pep[K211-T225] is able to rescue abnormal locomotor ac-
tivity and PPI, when it is observed, in Disc1-L100P mutant mice.
Disruption of the D2R-DISC1 Interaction Reverses
Amphetamine-Induced Hyperactivity and the Disruption
of PPI Induced by Apomorphine in Both Mice and Rats
Amphetamine induces hyperactivity primarily by releasing DA
and activating the D2R, and this is often used as a behavioral
test relevant to schizophrenia (Featherstone et al., 2007). Thus,1310 Neuron 84, 1302–1316, December 17, 2014 ª2014 Elsevier Incwe examined the effects of TAT-D2pep[K211-T225] on amphet-
amine-induced hyperactivity and apomorphine-induced PPI def-
icits. As shown in Figure 7C, TAT-D2pep[K211-T225] (1.5 nmol/g
i.p.) and haloperidol blocked amphetamine-induced hyperactiv-
ity in mice. The scrambled peptide TAT-D2pep-sc was inactive.
Neither TAT-D2pep[K211-T225] nor TAT-D2pep-sc affected base-
line locomotor activity in mice (Figure S8A).
PPI can be disrupted by the D1R/D2R agonist apomorphine.
Antipsychotics that have affinity for D2R such as haloperidol pre-
vent the apomorphine-induced deficits (Geyer et al., 2001; Ralph
and Caine, 2005). As shown in Figure 7D, apomorphine disrup-
ted PPI in comparison with saline (p < 0.05), and this effect
was blocked by haloperidol. TAT-D2pep[K211-T225] rescued
apomorphine-disrupted PPI in mice while TAT-D2pep-sc had
no effect. Neither peptide altered baseline startle response
(Table S5). TAT-D2pep[K211-T225] (intracerebroventricular
[i.c.v.] 4 nmol) also blocked amphetamine-induced hyperactivity
and apomorphine-induced disruption of PPI in rats (Figures 7E
and 7F). Neither TAT-D2pep[K211-T225] nor TAT-D2pep-sc
altered baseline locomotor activity or baseline startle response
in rats (Figure S8B; Table S6)..
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Although the interfering peptide we developed is able to amelio-
rate the schizophrenia-like behaviors, it is not of great clinical
utility if it also has side effects similar to current antipsychotics.
Because catalepsy is a strong predictor of EPS from antipsy-
chotics, we tested whether disruption of the DISC1-D2R interac-
tion induces catalepsy in rats. As shown in Figure 7G, haloperidol
(0.5 mg/kg s.c.) induced catalepsy, but TAT-D2pep[K211-T225]
(40 nmol, i.c.v.) did not, even at doses ten times higher than
doses that induced the behavioral responses presented above.
These data suggest that disruption of the DISC1-D2R interaction
may be a way to modulate D2R activity and exert antipsychotic
effects without causing acute EPS.
DISCUSSION
In summary, we have identified a possible target for the develop-
ment of antipsychotic treatment. This conclusion is based on: (1)
finding a protein complex composed of D2R and DISC1 that
facilitates D2R-mediated GSK-3 signaling, (2) an enhanced
D2R-DISC1 complex and decreased GSK-3 phosphorylation in
postmortem brain tissue from schizophrenia patients and
Disc1-L100P mice, and (3) developing an interfering peptide
that disrupts the D2R-DISC1 complex and reduces schizo-
phrenia-related behaviors without inducing catalepsy. Our pro-
posed model to integrate all these experimental observations is
shown in Figure 8. We posit that activation of D2R recruits
b-arrestins to D2R, which under physiological conditions has
two outputs that are in equilibrium: (1) in the presence of
DISC1, a b-arrestin-PP2A-Akt signaling complex forms, leading
to the activation of GSK-3 signaling, or (2) in the absence of
DISC1, a b-arrestin-clathrin-AP2 internalization complex forms,
leading to D2R internalization. In schizophrenia, however, exces-
sive dopamine release (Laruelle et al., 1996) combined with
elevatedD2R-DISC1complex levelswould lead tooveractivation
of the GSK3 pathway and a relative decrease in D2R internaliza-
tion. Thus, disrupting the DISC1-D2R complex with our peptide
may exert antipsychotic effects by restoring this equilibrium.
We found increased D2R-DISC1 interaction and decreased
GSK-3 phosphorylation in postmortem brain from schizophrenia
patients. A common confounding factor in such postmortem
brain samples is that of antipsychotic treatment. In our sample,
14 of the 15 schizophrenia patients received antipsychotic treat-
ment (Table S1). However, we argue that the higher DISC1-D2R
complex levels and lower GSK-3 phosphorylation are not conse-
quences of long-term antipsychotic treatment, because the
antipsychotic haloperidol blocks the increase in DISC1-D2R
complex formation (Figures S1F and S1G) and the decrease in
GSK-3 phosphorylation (Figures S6A–S6D) in Disc1-L100P
mice, where a hyperdopaminergic state is reported. Thus, anti-
psychotic medication has the opposite effect to the abnormal-
ities seen in the schizophrenia patients.
We also found that DISC1 facilitates D2R-mediated GSK-3
signaling through the D2R-DISC1 interaction. Previous studies
have shown that increased dopamine signaling and GSK3 activ-
ity are associated with psychosis (Laruelle et al., 1996; Beaulieu,
2012). Thus, an enhanced D2R-DISC1 interaction, leading to
increased GSK-3 activity, could contribute to psychotic symp-Netoms in schizophrenia. We are not claiming that the D2R-
DISC1 interaction itself is pathological, since it is also present
in unaffected human control subjects. Instead, we propose
that the hyperdopaminergic state seen in schizophrenia leads
to excessive D2R-DISC1 complex formation and abnormally
increased GSK-3 activity. Both could contribute to psychotic
symptoms.
We chose the striatum to characterize the functional role of the
D2R-DISC1 interaction because of the following: (1) all the
studies on the D2R-mediated GSK-3 pathway from Dr. Caron’s
group were conducted in striatum, including the effect of anti-
psychotics; (2) the vast majority of neurons (95%) within this
brain structure are medium spiny neurons (MSNs) (Nicola
et al., 2000; Surmeier et al., 2007), which are a principal site of
action of antipsychotic drugs because they express the highest
levels of D2R (Kellendonk et al., 2006); (3) striatal D2R occu-
pancy is strongly correlated with antipsychotic response (Agid
et al., 2007); and (4) MSNs participate in many of the cognitive
functions and behaviors that are altered in schizophrenia
(Simpson et al., 2010).
DISC1 is a scaffold protein that can modulate neurodevelop-
ment and neurotransmitter signaling in a number of brain
regions, through a large interactome (Duan et al., 2007; Kang
et al., 2011; Kim et al., 2009, 2012; Mao et al., 2009; Millar
et al., 2005; Singh et al., 2010). For example, DISC1 knockdown
reduces interactions with NDEL1 to result in premature cell cycle
exit and mispositioning of adult neurons in the adult hippocam-
pus. Similarly, in the embryonic cerebral cortex, DISC1 knock-
down reduces GSK3b, Wnt, and b-catenin interactions, also
resulting in premature cell-cycle exit and abnormal neuron
positioning. However, neuron migration is regulated by DISC1
interactions with Dixdc1 and NDEL, not GSK3. Furthermore,
development of the cortex is also regulated by phosphorylation
of DISC1, which regulates the transition from neuronal progeni-
tor proliferation to neuron migration (Ishizuka et al., 2011). These
examples illustrate that DISC1 has multiple effects in different
pathways. Thus, the D2R-DISC1 interaction may be just one of
many pathways through which DISC1 affects psychiatric illness.
Disc1-L100P mutant mice are hyperactive, with reduced PPI
compared to WT mice (Clapcote et al., 2007). In the present
study we have shown that disrupting the D2R-DISC1 complex
with TAT-D2pep[K211-T225] reversed these behavioral deficits
and blocked the reduction of GSK-3 phosphorylation. We are
aware of the fact that TAT-D2pep[K211-T225] increases the basal
phosphorylation of GSK3 (Figures 4E and 4F), which suggests
that D2pep[K211-T225] may inhibit endogenous dopamine tone.
In addition, hyperactivity induced by amphetamine, or disruption
of PPI induced by apomorphine, were reversed by TAT-D2pep
[K211-T225] in normal mice and rats. The effects of TAT-D2pep
[K211-T225] were specific to the particular amino acid sequence,
since the scrambled form of the peptide was inactive in all
tests. In these behavioral experiments the effects of TAT-
D2pep[K211-T225] were similar to those observed with the anti-
psychotic haloperidol, except that TAT-D2pep[K211-T225] did
not induce catalepsy. Overall, these results indicate that inter-
fering with the D2R-DISC1 complex using TAT-D2pep[K211-
T225] produces an antipsychotic-like response comparable to
haloperidol but devoid of EPS.uron 84, 1302–1316, December 17, 2014 ª2014 Elsevier Inc. 1311
Figure 7. Disruption of D2R-DISC1 Interaction Blocks Locomotor Hyperactivity and Restores PPI
(A) Effect of TAT-D2pep[K211-T225] on distance traveled (cm) in 30 min in the open-field. Disc1-L100P
/mutant mice (n = 9/16) andWT littermates (n = 8/8) were
treated with TAT-D2pep[K211-T225] or TAT-D2pep-sc (3 nmol/g i.p.) 30 min before testing. ANOVA detected a main effect of genotype (F(1, 49) = 6.35; p < 0.05),
peptide (F(1, 49) = 18.95; p < 0.001), testing interval (F(5, 245) = 63.07; p < 0.001), and their interactions (p’s < 0.05–0.001). # p < 0.05; ### p < 0.001—compared to
TAT-D2pep-sc-treated WT mice; *p < 0.05; ***p < 0.001—compared to TAT-D2pep-sc-treated mice within each genotype.
(B) Effect of TAT-D2pep[K211-T225] (3 nmol/g i.p.) on PPI in Disc1-L100P (n = 8/8) andWT (n = 8/8) mice. The TAT-D2pep[K211-T225] reversed PPI deficits inDisc1-
L100P mutants at all four prepulses. ANOVA detected a main effect of genotype (F(1, 42) = 21.9; p < 0.001), peptide (F(1, 42) = 40.3; p < 0.001), prepulses
(F(3, 126) = 24.6, p < 0.001), and gene x peptide interactions (F(2, 42) = 22.3, p < 0.001) on PPI. # p < 0.001—compared to TAT-D2pep-sc-treated WT mice;
***p < 0.001—compared to TAT-D2pep-sc-treated Disc1-L100P mutant mice.
(legend continued on next page)
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Figure 8. Schematic of Interactions be-
tween D2R and DISC1
Stimulation of D2R leads to recruitment of b-ar-
restins, which provide a balanced platform under
physiological conditions for either the formation of
the b-arrestin-PP2A-Akt signaling complex in the
presence of DISC1 or the b-arrestin-clathrin-AP2
internalization complex in the absence of DISC1.
Under pathological conditions, such as excess
stimulation of D2R in schizophrenia, the GSK3
pathway is overactive, while the D2R internaliza-
tion is downregulated.
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D2-DISC1 Complex and Antipsychotic EffectsAntipsychotic drugs have often been divided into typical and
atypical categories, with clozapine sometimes considered
distinct due to efficacy in refractory schizophrenia (Geddes
et al., 2000). Typical antipsychotics are D2R antagonists, while
atypical antipsychotics block D2R in combination with 5HT2A
receptors. D2R signaling is the primary target for antipsychotics
to exert their therapeutic effects, since no antipsychotics exist
that do not interact with D2Rs. However, D2Rs have a very com-
plex pattern of signal transduction, including both G protein-
dependent and G protein-independent Akt-GSK-3 pathways
(b-arrestin 2-dependent) (Missale et al., 1998; Beaulieu et al.,
2009). Thus, blockade of D2R with existing antipsychotics will
shut down all of these downstream signaling pathways, only
some of which may mediate the desired antipsychotic effect,(C) Effects of TAT-D2pep[K211-T225] (1.5 nmol/g i.p.) and haloperidol on hyperlocomotion induced by D-amph
mean ± SEM. For all groups, n = 8–12. TAT-D2pep[K211-T225] and HAL significantly reduced locomotion (F(3,
Tukey’s test p < 0.01).
(D) Effect of TAT-D2pep[K211-T225] (3 nmol/g i.p.) and haloperidol on apomorphine (APO)-induced PPI defi
baseline PPI but restored APO-disrupted PPI (pretreatment: F(3, 61) = 11.55, p < 0.001;  treatment F(1, 6
treatment F(3, 61) = 6.24, p < 0.01). Post hoc comparisons revealed that both TAT-D2pep[K211-T225] and HA
saline+APO versus TAT-D2pep[K211-T225]+APO; p < 0.001 for HAL+APO versus saline+APO; Turkey’s). #
compared to non-APO within each group. For all groups, n = 8–12.
(E) Effects of TAT-D2pep[K211-T225] (4 nmol, i.c.v.) and haloperidol on AMPH-induced hyperlocomotion in rat
effect treatment (F3, 21 = 9.641, p < 0.0001). For all groups, n = 6–8. Post hoc testing indicated that both
amphetamine-induced hyperactivity compared to saline. **p < 0.01; *p < 0.05.
(F) Effect of TAT-D2pep[K211-T225] (4 nmol, i.c.v.) and haloperidol on apomorphine (APO)-induced PPI defic
prepulses (70 dB, 75 dB, and 80 dB). A three-way ANOVA showed no effect ofTAT-D2pep[K211-T225] on ba
disrupted PPI (main effect of pretreatment: F(3, 72) = 4.24, p < 0.01; main effect of treatment F(1, 72) = 58.3,
F(3, 72) = 3.29, p < 0.05). Post hoc comparisons revealed that both TAT-D2pep[K211-T225] andHAL significantly
for comparisons HAL+APO versus saline+APO; ## p < 0.01 for comparisons saline+APO versusTAT-D2pep[
respective non-APO controls. For all groups, n = 8–12.
(G) Haloperidol (0.5 mg/kg s.c.) induced catalepsy but the TAT-D2pep[K211-T225] (40nmol, ICV) did not. HAL
(F(1,23) = 46.05; p < 0.001). For all groups, n = 8–12.
All data are shown as means ± SEM. See also Figures S7 and S8 and Tables S3–S6.
Neuron 84, 1302–1316, Dewhile othersmay be essential in maintain-
ing normal brain function.
Our strategy is to identify antipsychotic
drug targets by disrupting only some as-
pects of D2R signaling. Thus, antipsy-
chotic effects could result from a more
focused alteration of D2R signaling,
which would therefore have fewer side
effects. Antipsychotic drugs (including
haloperidol, clozapine, and olanzapine)
strongly block agonist-dependentrecruitment of b-arrestin 2 to the D2R, thus blocking D2R-medi-
ated modulation of GSK-3 signaling (Alimohamad et al., 2005).
Therefore, it is possible that antipsychotics affect GSK-3
signaling downstream of the D2R.
Our results demonstrate that the D2R-DISC1 complex is
involved in D2R-mediated GSK-3 signaling, but not signaling
via the G protein-dependent PKA pathway. This may explain
why our interfering peptide exerts antipsychotic effects without
inducing EPS. However, our data do not address the question
of whether the PKA pathway is associated with EPS. If this
were so, a PKA inhibitor would prevent EPS, but again, since
the PKA pathway has multiple physiological functions, complete
blockage of PKA pathway could lead to side effects as well. For
the same reason, a strong GSK-3 inhibitor might not be suitableetamine (AMPH: 1 mg/kg i.p.). All values represent
30) = 46.68, p < 0.001, two-way ANOVA; post hoc
cits in mice. TAT-D2pep[K211-T225] did not affect
1) = 37.93, p < 0.01; interaction treatment 3 pre-
L rescued PPI deficits (p < 0.001 for comparisons
p < 0.01 compared to saline +APO; **p < 0.001
s. One-way ANOVA analysis revealed a significant
haloperidol and TAT-D2pep significantly reduced
its in rats. The peptide reversed PPI deficits at all
seline PPI but showed a rescue of apomorphine-
p < 0.001; interaction of treatment 3 pretreatment
reversed the PPI deficit induced by APO. #p < 0.05
K211-T225] +APO; ***p < 0.001—in comparison with
induced catalepsy in comparison to other groups
cember 17, 2014 ª2014 Elsevier Inc. 1313
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rent data suggest that D2pep[K211-T225] has no effect on D2R-
mediated cAMP accumulation, we were not able to rule out the
possibility that other D2R signaling components might be
involved. For example, previous studies have suggested that
D2R interacts with prostate apoptosis response 4 (Par-4) and
calmodulin through the 212-241 region of D2R (Bofill-Cardona
et al., 2000; Park et al., 2005). The Par-4/D2R interaction is
involved in the D2R-mediated PKA pathway.
In conclusion, we have identified a specific target with antipsy-
chotic-like effects that is associated with D2R-mediated GSK-3
signaling, but not other D2R-mediated signaling pathways or
other GSK-3-mediated pathways. This provides an opportunity
to develop antipsychotics with fewer side effects. In particular,
the lack of catalepsy strongly suggests that interfering with the
D2R-DISC1 interaction should not cause EPS. The overall strat-
egy of targeting interactions between receptors and other pro-
teins could represent a general approach to improve efficacy
and reduce side effects for other medications.
EXPERIMENTAL PROCEDURES
A brief summary is provided here, with more details in the Supplemental Infor-
mation accompanying this article.
Coimmunoprecipitation, Protein Affinity Purification, In Vitro
Binding, and Western Blot
Protein affinity purification, in vitro binding, coimmunoprecipitation, and west-
ern blot analysis were performed as previously described (Lee et al., 2007; Pei
et al., 2010). For antibody details, see the Supplemental Experimental
Procedures.
GST Fusion Protein Constructs
GST-fusion proteins encoding D2R and DISC1 fragments were amplified by
PCR from full-length human cDNA clones. All constructs were sequenced to
confirm the absence of spurious PCR-generated nucleotide errors. GST fusion
proteins were prepared from bacterial lysates as described by the manufac-
turer (Amersham).
cAMP Accumulation Assay
cAMP accumulation assays were performed in HEK293T cells transiently
transfectedwith the indicated cDNA constructs and in striatal neurons infected
with DISC1 in lentiviral vector using the Parameter cAMP Assay Kit as directed
by the manufacturer (R&D systems, Minneapolis).
Lentivirus Production
Lentivirus was produced as previously described in our lab (Zhai et al., 2013).
DISC1 shRNA and shRNA-resistant DISC1 (DISC1R) in lentiviral vector were
gifts from Dr. Guo-li Ming at Johns Hopkins University. The lentivirus pack-
aging was done using X-tremegene HP transfection reagent.
Receptor Internalization with Surface Biotinylation
Biotinylation assay were performed as previously described (Lee et al., 2007).
Anti-HA or anti-D2R was used to detect the internalized D2Rs. Negative
control: biotin is cleaved before agonist stimulation (right after biotinylation).
Positive control: biotin is not cleaved after biotinylation.
Animals
Each experiment was performed on separate groups of 12- to 16-week-old
male mice or 10- to 12-week-old male Sprague-Dawley rats (200–225 g).
Disc1-L100P homozygous mutant mice and their WT littermates were gener-
ated as previously described. For drug and peptide doses and administration
routes, see the Supplemental Experimental Procedures.1314 Neuron 84, 1302–1316, December 17, 2014 ª2014 Elsevier IncBehavioral Experiments
Locomotor activity testing in mice and rats was performed according to previ-
ously published methods (Lee et al., 2007; Pei et al., 2010). PPI in mice was
slightly modified from previously published descriptions (Clapcote et al.,
2007). Rat PPI was assessed using six SR-Lab Startle Response systems
(San Diego Instruments, San Diego) as previously described (Sills, 1999).
Catalepsy was measured in rats as described previously (Creed-Carson
et al., 2011).
Statistical Analyses
Data were analyzed by one-, two-, or three-way ANOVA, followed where
appropriate by post hoc Fishers LSD test. Bonferroni corrections were applied
in cases of multiple comparisons (Statistica, Statsoft, Tulsa).
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